Biomanufacturing demand will drive revenues for Patheon according to an Evercore ISI analyst, who has predicted the newly-listed CDMO will strengthen its capabilities through M&A.
Pfizer has temporarily halted production at a former-Hospira aseptic plant in Chennai, India after regulators observed manufacturing issues during an inspection in June.
Endo International says it intends to expedite a cost-saving plan by closing a manufacturing site in North Carolina and reducing headcount at another in Alabama.
Controlled substances and peptides are on AMRI’s wish list as it profits from a growth strategy which has seen six acquisitions over the past two years.
The Pfizer-Allergan $160bn merger will create the world’s largest pharma company but potentially not for long, as the two CEOs discuss breaking the entity up in 2018.
Pfizer says it will decide in 2018 whether to split its generics and branded businesses but M&A experts are already predicting how the giant will get rid of its established drugs programme.
Unilife CEO Alan Shortall yesterday confirmed the drug delivery company is still “receiving interest from several parties under the strategic review process” and set a deadline of December 31 to announce any potential takeover. The company received its...
AMRI attributed recent M&A activity to passing the $100m (€93m) quarterly sales milestone, reporting high double-digit growth across its API and small-scale manufacturing divisions.
As pharma sells off manufacturing capacity and outsources to large and specialist CMOs, smart contract houses will have an opportunity to grab market share in a currently fragmented sector, say experts.
An advisor to the pharma industry on M&A says the current boom in pharma valuations will not last, and R&D cost pressures will reshape firms of the future.
The huge former Ben Venue injectables manufacturing plant in Ohio that became the center of controversy over drug shortages a few years ago remains off line, and the company that now owns the site reiterated this week that it has no plans to resume making...
Industry headhunters have picked their top CEOs in European pharma, saying the most successful investors keep chief execs in place even through hard times.
Celgene has shelled out $7.2bn (€6.6bn) to acquire Receptos which is developing an oral lymphocyte trafficking agent for multiple sclerosis and inflammatory bowel disorder.
The proposed Perrigo merger with Mylan would be of no benefit to either firm in the “highly competitive” OTC sector, according to financial analysts BMO.
Demand for CNS assets will help break records for pharma M&As in 2015, Neel Patel, VP of inVentiv Health consultancy Campbell Alliance, tells in-Pharmatechnologist.com.
Ex-Allergan CEO David Pyott has spoken of his “total war” battling Valeant’s failed hostile takeover, and given advice to other pharmaceutical companies on how to deal with activist shareholders.
UPDATE - Mylan demands a straightforward answer to whether Teva will make a legally binding exchange offer
Teva has refuted accusations of “meddling” with Mylan’s business in the latest chapter of what one analyst says is a far from friendly, if not hostile takeover attempt.
Teva has been accused of "playing games" with Mylan by acquiring a 1.35% stake in the generics firm weeks after having a $40bn (EUR36bn) takeover bid snubbed.
Merck KGaA is confident it will close the $17bn acquisition of Sigma-Aldrich in mid-2015 despite competition concerns from the European Commission (EC).
Endo’s $8bn takeover of Par Pharmaceutical is expected to shake-up the generics sector, while Lupin is expanding its South American network – welcome to In-Pharmatechnologist’s M&A round-up.
BASF says it remains committed to the pharma industry despite plans to divest its custom synthesis business and around 100 APIs and intermediates to Siegfried Holding.
Pfizer reduced costs 40% without cutting jobs at a facility in Sweden using an alternative approach to organisational and cultural behaviour, and hopes to do the same at its newly acquired Austrian plant.
A merger with Mylan would “transform the global generics space” says Teva, which has entered a $40bn bid as an alternative to the recently proposed Mylan-Perrigo deal.
